| ANCOVA | analyses of covariance |
| AVH | auditory verbal hallucinations |
| BACS | Brief Assessment of Cognition in Schizophrenia |
| CDSS | Calgary Depression Scale for Schizophrenia total score |
| CGI | Clinical Global Impression |
| CIAS | Cognitive Impairment Associated with Schizophrenia |
| DLPFC | Dorsolateral Prefrontal Cortex |
| EEG | Electroencephalography |
| FGAs | first-generation antipsychotics |
| GABA | γ-Aminobutyric acid |
| LAI | Long Acting Injectable |
| LTD | long-term depression |
| LTP | long-term potentiationNIBS—Non-Invasive Brain Stimulation |
| NMDA | N-methyl-D-aspartate |
| NS | Negative symptoms |
| NoSM | Non-Smoker patients |
| PANSS | Positive and Negative Symptoms Scale |
| PLWS | people living with schizophrenia |
| RCT | randomized controlled trial |
| rTMS | repetitive transcranial Magnetic Stimulation |
| SGAs | second-generation antipsychotics |
| SM | Smoker patients |
| T | timepoint |
| tDCS | transcranial Direct Current Stimulation |